Beike Biotech

Lupus study shows promising results using umbilical cord mesenchymal stem cells.

NANJING, Jiangsu, China, June 7, 2010 /PRNewswire-Asia/ -- A new study shows that umbilical cord mesenchymal stem cell transplant (UC-MSCT) may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus (SLE).

In research published online (ahead of print) May 6, 2010 in Arthritis & Rheumatism, lead author and Director of Rheumatology and Immunology at Nanjing University Medical School's renowned Drum Tower Hospital Dr. Lingyun Sun and colleagues report on 16 patients with severe SLE that did not respond to standard treatments. All 16 patients received stem cell transplants. Ten patients completed at least 6 months of follow-up and 2 patients were followed for more than 2 years. There was no treatment-related mortality or other adverse event during or after UC-MSCT, according to the article.

New Center Integrates Traditional Chinese, Romanian and Western Therapies

CAMPINA and PRAHOVA, Romania, July 20 /PRNewswire-Asia/ -- Beike Biotechnology Co. Ltd. (http://www.beikebiotech.com/index.php ), one of the world's leading biotechnology companies focusing on adult stem cell therapies, opened Romania's first rehabilitation center to use traditional Chinese-style rehabilitation techniques in Campina today.

The new Romanian center is Beike's first stand-alone rehabilitation facility in the world. Physical rehabilitation is a key component of Beike's stem cell therapy protocols which are utilized by leading hospitals throughout China. In conjunction with each one-month stem cell treatment cycle, most patients undergo extensive physical therapy and rehabilitation in an effort to enhance the effects of the stem cells. Chinese patients are able to continue with the rehabilitation after the treatment is completed, but often overseas patients can not find affordable therapy when they return home.

The new 240 square-meter center provides traditional Chinese acupuncture, massage, physical therapy, physiotherapy, electrotherapy and medical exercise-based techniques to help patients with neurological and autoimmune diseases such as ataxia, multiple sclerosis, cardiovascular disease, spinal cord injuries and autoimmune disorders, among others.

"Beike Holdings Limited", a Strategic Joint Venture With Bangkok-Based SiriCell Technologies, Inc., Will Support the Rapid Clinical Translation of Stem Cell Therapies & Regulatory Approval Outside of China

SHENZHEN, China, June 10 /PRNewswire-Asia/ -- Shenzhen Beike Biotechnology Co. Ltd. ("Beike") ( http://www.beikebiotech.com ), China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited ("Beike Holdings") a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers. The joint venture is actively constructing a regional network of world class cGMP stem cell manufacturing labs, distribution centers and storage banks to service and support its hospital training and clinical advisory services.

Beike's stem cells have been shown to be safe and effective in therapies based on direct clinical observation in the hospital setting. Beike Holdings will fund and oversee a series of comprehensive, multi-centered, adaptive Phase 1 and 2 clinical trials to advance the ongoing clinical validations of the safety and efficacy of Beike's stem cell therapies to patients throughout Southeast Asia.

Leading Chinese Stem Cell Therapy Provider Expands Capacity Ahead of Schedule

TAIZHOU, China, May 11 /PRNewswire-Asia/ -- Beike Biotechnology Co. Ltd., one of the world's leading biotechnology companies focusing on adult stem cell therapies, and the Jiangsu government's China Medical City (CMC) opened China's state-of-the-art stem cell storage and processing facility today.  The 20,000 square-meter Stem Cell Regenerative Medicine Industrial Project of National Bio-Industry Base (NBPD) houses China's first comprehensive regenerative medicine technology center and its largest international stem cell bank.

The Stem Cell Regenerative Medicine Industrial Facility gives Beike the capacity to store and process 1 million copies of stem cells, making it the largest and most sophisticated stem cell processing center of its kind in the world. The visionary leadership of the Jiangsu Government and Beike set the stage for this advancement when the partnership broke ground on the project one year ago. The NBPD facility is part of multi-stage project that consists of industry partnerships designed to provide a central research zone for China's regenerative medicine and bio-medical industry. Groups collaborating on this biotechnology incubation center include those from Fudan University, Huazhong Science and Technology University, Nanjing University Medical School, Jiangsu University, Shanghai Jiao Tong University and Jiangsu Provincial People's Hospital.

"Stem cells are the crown jewel of medical research," said Dr. Ying Song, the center's newly appointed VP for Medical, Scientific and Regulatory Affairs. "We are honored China Medical City has chosen Beike as a partner to support China's role as a world leader in stem cell technology. Scientists all over the world -- not just in China but in places like the U.S. and other developed Western countries -- are engaged in the same work we are here in China Medical City. We believe our work will serve as a model for them as we conduct this important research designed to bring life-changing stem cell therapies to patients."